Resveratrol inhibits hypoxia-induced glioma cell migration and invasion by the p-STAT3/miR-34a axis.
@article{Wang2016ResveratrolIH, title={Resveratrol inhibits hypoxia-induced glioma cell migration and invasion by the p-STAT3/miR-34a axis.}, author={H. Wang and H. Feng and Y. Zhang}, journal={Neoplasma}, year={2016}, volume={63 4}, pages={ 532-9 } }
Hypoxia promotes aggressiveness, angiogenesis and resistance in glioma. It has been reported that resveratrol has strong anti-tumor ability and can inhibit migration and invasion of varieties of tumor including glioma. However, whether resveratrol inhibits hypoxia-induced migration and invasion of glioma cells is still unknown. In this study, we found glioma U87 and U251 cells migration and invasion was reduced by resveratrol under hypoxia condition and higher doses led to stronger block, while… CONTINUE READING
13 Citations
Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis.
- Biology, Medicine
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- 2017
- 39
Advances in the targeting of HIF-1α and future therapeutic strategies for glioblastoma multiforme (Review).
- Biology, Medicine
- Oncology reports
- 2017
- 16
- PDF
Regulatory role of resveratrol, a microRNA-controlling compound, in HNRNPA1 expression, which is associated with poor prognosis in breast cancer
- Medicine
- Oncotarget
- 2018
- 22
- PDF
Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer
- Chemistry, Medicine
- International journal of molecular sciences
- 2019
- 21
- PDF
Anti-Stress, Glial- and Neuro-Differentiation Potential of Resveratrol: Characterization by Cellular, Biochemical and Imaging Assays
- Biology, Medicine
- Nutrients
- 2020
- 2
- PDF
Herbal nutraceuticals: safe and potent therapeutics to battle tumor hypoxia
- Medicine
- Journal of Cancer Research and Clinical Oncology
- 2019
- 2
Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems.
- Medicine
- Current medicinal chemistry
- 2019
- 2
Clinicopathological and Prognostic Roles of STAT3 and Its Phosphorylation in Glioma
- Medicine
- Disease markers
- 2020
References
SHOWING 1-10 OF 61 REFERENCES
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells.
- Biology, Medicine
- Cancer letters
- 2009
- 393
Activated STAT3 Regulates Hypoxia-Induced Angiogenesis and Cell Migration in Human Glioblastoma
- Biology, Medicine
- Neurosurgery
- 2010
- 46
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.
- Medicine, Biology
- The Journal of clinical investigation
- 2014
- 443
- Highly Influential
- PDF
Hypoxia-Induced Down-Regulation of microRNA-34a Promotes EMT by Targeting the Notch Signaling Pathway in Tubular Epithelial Cells
- Biology, Medicine
- PloS one
- 2012
- 140
- PDF
MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1
- Medicine
- Clinical and Experimental Medicine
- 2012
- 227
MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3
- Biology, Medicine
- Oncotarget
- 2015
- 106
- PDF
miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinoma
- Biology, Medicine
- Laboratory Investigation
- 2015
- 28
- PDF
Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells.
- Medicine
- International journal of radiation oncology, biology, physics
- 2010
- 60
Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells.
- Biology, Medicine
- International journal of oncology
- 2010
- 67
Involvement of ROS-alpha v beta 3 integrin-FAK/Pyk2 in the inhibitory effect of melatonin on U251 glioma cell migration and invasion under hypoxia
- Medicine
- Journal of Translational Medicine
- 2015
- 35